Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Additive Manufacturing in Pharmaceuticals / / edited by Subham Banerjee
| Additive Manufacturing in Pharmaceuticals / / edited by Subham Banerjee |
| Autore | Banerjee Subham |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (378 pages) |
| Disciplina | 615.6 |
| Soggetto topico |
Pharmaceutical chemistry
Drug delivery systems Pharmacology Pharmaceutics Drug Delivery |
| ISBN |
9789819924042
9819924049 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. History and Present Scenario of Additive Manufacturing in Pharmaceuticals -- 2. Fused deposition modeling (FDM) of Pharmaceuticals -- 3. Stereolithography (SLA) in Pharmaceuticals -- 4. Selective Laser Sintering (SLS) In Pharmaceuticals -- 5. Semi-solid Extrusion (SSE) in Pharmaceuticals -- 6. Inkjet and Binder Jet Printing in Pharmaceuticals -- 7. 4D printing: The next dimension of healthcare in cancer research -- 8. 4D Printing in Pharmaceuticals -- 9. Bioprinting in Pharmaceuticals -- 10. Regulatory Perspective of Additive Manufacturing in the Field of Pharmaceuticals -- 11. Machine Learning in Additive Manufacturing of Pharmaceuticals. . |
| Record Nr. | UNINA-9910746101003321 |
Banerjee Subham
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced Drug Delivery : Methods and Applications / / edited by Tuhin Subhra Santra, Ashwini Uma Surendra Shinde
| Advanced Drug Delivery : Methods and Applications / / edited by Tuhin Subhra Santra, Ashwini Uma Surendra Shinde |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (368 pages) |
| Disciplina | 615.6 |
| Collana | Studies in Mechanobiology, Tissue Engineering and Biomaterials |
| Soggetto topico |
Drug delivery systems
Biomedical engineering Nanobiotechnology Microfluidics Cytology Pharmaceutical chemistry Drug Delivery Systems Nanoparticle Drug Delivery System Technology, Pharmaceutical Drug Delivery Biomedical Engineering and Bioengineering Cell Biology Pharmaceutics |
| ISBN | 981-9965-64-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Biological methods -- Chapter 2. Liposomal based drug delivery system -- Chapter 3. Hydrogel-based drug delivery strategies -- Chapter 4. Monoclonal antibodies -- Chapter 5. Electroporation -- Chapter 6. Photoporation -- Chapter 7. Mechanoporation -- Chapter 8. Magnetoporation -- Chapter 9. Microinjection -- Chapter 10. Jet injection -- Chapter 11. Sonoporation -- Chapter 12. Device based drug delivery techniques – microfluidics Chapter 13. Nanoparticles drug delivery systems -- Chapter 14. BioMaterials -- Chapter 15. Implanted drug delivery systems -- Chapter 16. Transdermal drug delivery systems -- Chapter 17. Subcutaneous drug delivery systems -- Chapter 18. Nasopulmonary drug delivery systems -- Chapter 19. Mucosal drug delivery systems -- Chapter 20. Intrauterine drug delivery systems -- Chapter 21. Gastro retentive drug delivery systems -- Chapter 22. Endoscopic assisted drug delivery -- Chapter 23. Theranostics. |
| Record Nr. | UNINA-9910754097503321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced drug delivery strategies for targeting chronic inflammatory lung diseases / / Dinesh Kumar Chellappan, Kavita Pabreja and Md. Faiyazuddin, editors
| Advanced drug delivery strategies for targeting chronic inflammatory lung diseases / / Dinesh Kumar Chellappan, Kavita Pabreja and Md. Faiyazuddin, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (652 pages) |
| Disciplina | 615.6 |
| Soggetto topico |
Drug delivery systems
Lungs - Diseases - Treatment Nanoparticles Malalties del pulmó Dispositius d'administració de medicaments |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
981-16-4392-X
981-16-4391-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- 1: An Introduction to Respiratory Diseases and an Emerging Need for Efficient Drug Delivery Systems -- 1.1 Current Treatments for Respiratory Diseases -- 1.1.1 Bronchodilators -- 1.1.2 Corticosteroids -- 1.1.3 Antibiotics -- 1.1.4 Bronchodilators -- 1.2 Challenges to the Current Treatment of Drugs -- 1.2.1 Asthma -- 1.2.2 Chronic Obstructive Pulmonary Disease (COPD) -- 1.2.3 Interstitial Lung Diseases (ILDs) -- 1.2.4 Cystic Fibrosis (CF) -- 1.2.5 Lung Cancer -- 1.2.6 Respiratory Infections -- 1.3 Pulmonary Drug Delivery Systems -- 1.4 Limitations of the Drug Delivery Systems -- 1.5 The Need of Novel Drug Delivery Systems -- 1.6 Conclusion -- References -- 2: Inflammatory Respiratory Diseases: Correlation Between Lung Cancer and COVID-19 -- 2.1 Epidemiology -- 2.1.1 Introduction -- 2.1.2 Incidence -- 2.1.3 Mortality -- 2.1.4 Survival -- 2.2 Lung Cancer Among Never Smokers -- 2.2.1 Risk Factors -- 2.2.1.1 Passive Smoking -- 2.2.2 Cooking Fumes -- 2.2.3 Inherited Genetic Susceptibility -- 2.2.4 Preexisting Lung-Related Disease -- 2.2.5 Clinical Profile of Lung Cancer Among Never Smokers -- 2.3 Lung Cancer Screening, Diagnosis, and Treatment -- 2.3.1 Screening -- 2.3.2 Diagnosis -- 2.3.2.1 PET with Computed Tomography (PET-CT) -- 2.3.2.2 Magnetic Resonance Imaging (MRI) -- 2.3.3 Bronchoscopy -- 2.3.3.1 Fiberoptic Bronchoscopy -- 2.3.4 Endobronchial Ultrasound (EBUS) and Endoscopic (Esophageal) Ultrasound (EUS) -- 2.3.5 Transthoracic Needle Biopsy -- 2.3.5.1 Treatment -- 2.3.5.2 Surgery -- 2.3.5.3 Chemotherapy -- 2.3.5.4 Targeted Therapy -- 2.3.5.5 Immunotherapy -- 2.3.5.6 Radiation -- 2.4 Lung Cancer and COVID-19 -- 2.4.1 Introduction -- 2.4.2 Lung Cancer to a COVID-19 Risk Factor -- 2.4.3 Why Are Lung Cancer Patients Prone to Getting Infected with COVID-19?.
2.4.4 Lung Cancer Management During Diagnosis and Staging -- 2.5 Conclusion -- References -- 3: Advancements in Translational Respiratory Research Using Nanotechnology -- 3.1 Introduction -- 3.2 Advancements in Translational Respiratory Research (TRR) -- 3.3 Overview of Nanomedicine and Nanotechnology -- 3.3.1 Types of Nanoparticles -- 3.3.1.1 Carbon-Based Nanoparticles -- 3.3.1.2 Metal Nanoparticles -- 3.3.1.3 Ceramic Nanoparticles -- 3.3.1.4 Semiconductor Nanoparticles -- 3.3.1.5 Polymeric Nanoparticles -- 3.3.1.6 Lipid-Based Nanoparticles -- 3.3.2 Synthesis of Nanoparticles -- 3.3.2.1 Bottom-Up Method -- 3.3.2.2 Top-Down Method -- 3.3.3 Characterization of Nanoparticles -- 3.4 Inhalation Drug Delivery -- 3.4.1 Barriers to the Inhalation Drug Delivery System -- 3.4.2 Nanoparticles in Inhalation Drug Delivery -- 3.4.3 Clinical Studies on Inhalation Drug Delivery -- 3.5 Oligonucleotide Therapy -- 3.5.1 Antisense Oligonucleotides (ASOs) -- 3.5.2 Short Interfering RNA (siRNA) -- 3.5.3 MicroRNA (miRNA) -- 3.5.4 Aptamers -- 3.5.5 Cytosine-Guanine Dinucleotide (CpG) Oligonucleotides -- 3.5.6 Delivery of Oligonucleotide Therapy -- 3.5.7 Clinical Studies on Oligonucleotide Therapy -- 3.6 Photodynamic Therapy (PDT) -- 3.6.1 Nanoparticles in PDT -- 3.6.2 Clinical Studies on Photodynamic Therapy -- 3.7 Future Prospects -- 3.8 Conclusion -- References -- 4: Chemical Moieties as Advanced Therapeutics for Targeting Respiratory Disorders -- 4.1 Introduction -- 4.2 Indole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.3 Azole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.4 Chromone-Based Conjugates for Capping Respiratory Disorders -- 4.5 Flavonoid-Based Conjugates for Capping Respiratory Disorders -- 4.6 Terpenoid-Based Conjugates for Capping Respiratory Disorders -- 4.7 Alkaloids for Capping Respiratory Disorders. 4.8 Essential Patented Molecules for Ameliorating Respiratory Disorders -- 4.9 Conclusion -- References -- 5: Phytochemicals and their Nanoformulations Targeted for Pulmonary Diseases -- 5.1 Introduction -- 5.2 Phytochemical Nanoformulations Targeted for Lung Diseases -- 5.2.1 Curcumin -- 5.2.2 Resveratrol -- 5.2.3 Naringenin -- 5.2.4 (-)-Epigallocatechin-3-O-Gallate (EGCG) -- 5.2.5 Berberine -- 5.2.6 Celastrol -- 5.3 Conclusion and Future Prospects -- References -- 6: Nanocarriers: An Advanced and Highly Effective Approach for Targeting Chronic Lung Diseases -- 6.1 Introduction -- 6.2 Advanced Drug Delivery and Its Implication in Chronic Inflammatory Lung Disease -- 6.3 Nanocarriers Investigated in Advanced Drug Delivery for Targeting Chronic Lung Disease -- 6.3.1 Liposomes -- 6.3.2 Dendrimers -- 6.3.3 Polymeric Nanoparticles -- 6.3.4 Micelles -- 6.3.5 Carbon Nanotubes -- 6.3.6 Quantum Dots -- 6.3.7 Exosomes -- 6.3.8 Solid Lipid Nanoparticles -- 6.4 Synthetic Approaches of Polymeric Nanoparticle Formulation -- 6.5 Drugs Delivered Through Advanced Drug Delivery Strategies: Nanocarriers -- 6.6 Conclusions and Future Prospects -- References -- 7: Vesicular Drug Delivery Systems in Respiratory Diseases -- 7.1 Introduction -- 7.2 Global Prevalence of Major Respiratory Diseases -- 7.3 Conventional Therapies Used for Respiratory Diseases -- 7.4 Antibiotics -- 7.5 Anti-Inflammatory Drugs -- 7.6 Bronchodilators -- 7.7 Gene Therapy -- 7.8 Vesicular Drug Delivery System (VDDS) for Respiratory Disease Treatment -- 7.8.1 Liposomes -- 7.8.2 Virosomes -- 7.8.3 Niosomes -- 7.8.4 Proniosomes -- 7.8.5 Archaesome -- 7.8.6 Ethosomes -- 7.8.7 Others -- 7.9 Conclusion and Future Perspective -- References -- 8: Nanoparticles in Chronic Respiratory Diseases -- 8.1 Introduction -- 8.1.1 Chronic Respiratory Disease -- 8.1.2 Nanoparticle Size for Alveoli Delivery. 8.2 Lipid-Based Nanoparticle -- 8.2.1 Liposomes -- 8.2.2 Lipid Polymer Hybrid -- 8.2.3 Solid Lipid Nanoparticle -- 8.2.4 Nanostructured Lipid Carrier -- 8.3 Polysaccharides-Based Nanoparticles -- 8.4 Polymer-Based Nanoparticles (PNS) -- 8.5 Dendrimers -- 8.6 Inorganic Nanoparticles -- 8.6.1 Development of Inorganic Nanoparticles -- 8.6.1.1 Precipitation of Salts in Aqueous Media -- 8.6.1.2 Hydrothermal Method -- 8.6.1.3 Microemulsion Method -- 8.6.1.4 Polyol Process -- 8.6.1.5 Thermal Decomposition -- 8.6.2 Inorganic-Based Nanomaterials -- 8.6.2.1 Carbon Nanotubes -- 8.6.2.2 Gold Nanoparticles -- 8.6.2.3 Silver Nanoparticles -- 8.6.2.4 Platinum Nanoparticles -- 8.6.2.5 Magnetic Nanoparticles (MNPs) -- 8.6.2.6 Iron-Oxide Nanoparticles -- 8.6.2.7 Zinc Oxide Nanoparticles -- 8.6.2.8 Copper Oxide Nanoparticle -- 8.6.3 Inorganic Nanoparticles in Chronic Respiratory Diseases -- 8.7 Advanced Nanomedicine for Chronic Respiratory Diseases -- 8.7.1 Clinical Studies for Targeted Drug Delivery -- 8.7.1.1 Cystic Fibrosis -- 8.7.1.2 Lung Cancer -- 8.7.1.3 Asthma -- 8.7.2 Theranostics (Diagnosis and Imaging Based on Nanotechnology) -- 8.8 Conclusion -- References -- 9: Applications of Nanotechnology in Pulmonary Disease Diagnosis -- 9.1 Introduction -- 9.2 Promising Nanotechnological Interventions for Pulmonary Disease Diagnosis -- 9.2.1 Nanoparticle-Based Nano-Platforms for Diagnostic Imaging in Pulmonary Diseases -- 9.2.1.1 Gold NPs -- 9.2.1.2 Iron Oxide NPs -- 9.2.1.3 Polymeric NPs -- 9.2.1.4 Silica-Based NPs -- 9.2.1.5 Manganese Oxide NPs -- 9.2.1.6 Gadolinium-Based NPs -- 9.2.1.7 Miscellaneous -- 9.3 Nano-Biosensors for Pulmonary Disease Diagnosis -- 9.3.1 Nano-Biosensors for the Diagnosis of Tuberculosis -- 9.3.2 Nano-Biosensors for the Diagnosis of Lung Cancer -- 9.3.3 Nano-Biosensors for Diagnosis of Pulmonary Arterial Hypertension. 9.4 Quantum Dots/Nanocrystal Fluorophores-Based Nano-Platforms for Pulmonary Disease Diagnosis -- 9.5 Conclusion and Future Perspectives -- References -- 10: Nanotechnology in Pulmonary Disease Diagnosis -- 10.1 Introduction -- 10.2 Nanotechnology as a Diagnosis Tool -- 10.2.1 Ex Vivo Diagnosis -- 10.2.2 In Vivo Diagnosis -- 10.3 Nanotechnology in the Diagnosis of Pulmonary Diseases -- 10.4 Summary and Conclusion -- References -- 11: Recent Trends in Nanomedicine for Diagnosis and Treatment of Pulmonary Diseases -- 11.1 Introduction -- 11.1.1 Classification of Respiratory Diseases -- 11.1.2 Nanomedicine -- 11.1.3 Application of Nanomedicine in Respiratory Diseases -- 11.1.4 Diagnosis and Treatment -- 11.1.5 Obstructive Pulmonary Diseases -- 11.1.6 Pulmonary Tuberculosis -- 11.1.7 Lung Cancer -- 11.2 Targeted Drug Delivery in Pulmonary Diseases -- 11.3 Types of Nanoparticle-Based Treatment for Pulmonary Diseases -- 11.3.1 Solid Lipid Nanoparticles (SLN) -- 11.3.2 Polymeric Nanoparticles -- 11.4 Conclusion and Future Perspectives -- References -- 12: Strategies for Enhanced Drug Targeting to Inflamed Lungs: Novel Perspectives -- 12.1 Introduction -- 12.2 Anatomy and Physiology of Human Lungs -- 12.2.1 Bronchial Tree -- 12.2.1.1 Tracheal Airways -- 12.2.1.2 Bronchi and Bronchioles -- 12.2.2 Alveoli -- 12.2.3 Pulmonary Blood Circulation -- 12.2.4 Physiology of Lungs -- 12.2.4.1 Pulmonary Mechanics -- 12.2.4.2 Inspiration -- 12.2.4.3 Expiration -- 12.2.4.4 Gas Exchange -- 12.3 Chronic Inflammatory Lung Diseases -- 12.3.1 Asthma -- 12.3.1.1 Pathogenesis of Asthma -- 12.3.2 Chronic Obstructive Pulmonary Disease (COPD) and Emphysema -- 12.3.2.1 Pathogenesis of COPD (Chronic Bronchitis and Emphysema) -- 12.3.3 Idiopathic Pulmonary Fibrosis (IPF) -- 12.3.3.1 Pathogenesis of IPF -- 12.4 Nanodiagnosis of CILD. 12.5 Strategies for Enhanced Drug Targeting to Inflamed Lungs. |
| Record Nr. | UNINA-9910743341503321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advanced Drug Delivery Systems / / Bhupendra Prajapati, editor
| Advanced Drug Delivery Systems / / Bhupendra Prajapati, editor |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2023 |
| Descrizione fisica | 1 online resource (170 pages) |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| ISBN | 1-80356-984-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910678588403321 |
| London : , : IntechOpen, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Novel Formulations for Drug Delivery / / edited by Raj K. Keservani, Rajesh Kumar Kesharwani, and Anil K. Sharma
| Advances in Novel Formulations for Drug Delivery / / edited by Raj K. Keservani, Rajesh Kumar Kesharwani, and Anil K. Sharma |
| Pubbl/distr/stampa | Hoboken, NJ ; ; Beverly, MA : , : John Wiley & Sons, Inc. : , : Scrivener Publishing LLC, , [2023] |
| Descrizione fisica | 1 online resource (576 pages) |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| ISBN |
1-394-16770-9
1-394-16769-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Part I: Novel Drug Carriers and Therapeutics -- Chapter 1 Nanoarchitectured Materials: Their Applications and Present Scenarios in Drug Delivery -- 1.1 Introduction -- 1.2 Liposomes -- 1.3 Nanoparticles -- 1.3.1 Nanoparticles in Drug Delivery -- 1.4 Nanoemulsions -- 1.4.1 Advantages and Shortcomings of Nanoemulsions -- 1.4.2 Application of Nanoemulsion in Drug Delivery -- 1.5 Dendrimers -- 1.5.1 Synthesis of Dendrimers -- 1.5.2 Advantages of Dendrimers -- 1.5.3 Applications of Dendrimers in Drug Delivery -- 1.6 Aquasomes -- 1.6.1 Properties of Aquasomes -- 1.6.2 Application of Aquasomes in Drug Delivery -- 1.7 Nanogel -- 1.7.1 Properties of Nanogels -- 1.7.2 Nanogels in Drug Delivery -- 1.8 Quantum Dots -- 1.8.1 Applications of Quantum Dots in Drug Delivery -- 1.9 Carbon Nanotubes -- 1.9.1 Features of Carbon Nanotubes -- 1.9.2 Carbon Nanotubes in Drug Delivery -- References -- Chapter 2 Nanopharmaceuticals for Drug Delivery -- 2.1 Introduction -- 2.2 What Are Nanopharmaceuticals and What Do They Do? -- 2.3 Nanopharmaceuticals Importance -- 2.4 Nanotechnology -- 2.5 Pharmaceutical Companies and Nanotechnology -- 2.6 Applications and Advantages of Nanopharmaceuticals as Drug Carriers -- 2.7 Characteristics of Nanoparticles in Nanopharmaceuticals -- 2.7.1 Particle Size -- 2.7.2 Surface Properties of Nanoparticles -- 2.7.3 Drug Loading -- 2.7.4 Drug Release -- 2.8 Targeted Drug Delivery -- 2.9 Types of Nanoparticles -- 2.10 Nanoparticle Preparation Methods -- 2.11 Evaluation of Nanoparticles -- 2.12 Efficiency of Drug Entrapment -- 2.13 Particle Shape -- 2.14 Size of the Particles -- 2.15 Zeta Potential -- 2.16 Rise of Nanopharmaceuticals -- 2.17 Nanopharmaceuticals Approval Regulations (FDA Rules & -- Regulations) -- 2.18 Conclusions and Prospects for the Future -- References.
Chapter 3 Applications and Prospects of Nanopharmaceuticals Delivery -- 3.1 Introduction -- 3.2 Nanopharmaceuticals -- 3.3 Development of Nanopharmaceuticals -- 3.3.1 From Lab to the Marketplace -- 3.3.2 Techniques -- 3.3.3 Cost -- 3.3.4 Ethics -- 3.3.5 Nanopharmaceuticals Approval Regulations (FDA Rules & -- Regulations) -- 3.4 Clinical Applications of Nanotechnology -- 3.4.1 Diagnostic Applications -- 3.4.1.1 Detection -- 3.4.1.2 Protein Chips -- 3.4.1.3 Individual Target Probes -- 3.4.1.4 Nanotechnology as a Tool in Imaging -- 3.4.1.5 Sparse Cell Detection -- 3.4.2 Therapeutic Applications -- 3.4.2.1 Surfaces -- 3.4.2.2 Gene Delivery -- 3.4.2.3 Drug Delivery -- 3.4.2.4 Liposomes -- 3.4.2.5 Nanotechnology in Orthopedic Applications -- 3.4.2.6 Nanotechnology in Cardiac Therapy -- 3.4.2.7 Nanotechnology in Dental Care -- 3.4.2.8 Biomolecular Engineering -- 3.4.2.9 Biopharmaceuticals -- 3.5 Nanopharmaceuticals Delivery-Recent Applications -- 3.5.1 Nanoparticulate Systems for Vaccine -- 3.5.1.1 Polyanhydride-Based NPs -- 3.5.1.2 Biodegradable Synthetic PLGA NPs -- 3.5.1.3 Liposome-Based NPs -- 3.5.1.4 Polysaccharide-Based NPs -- 3.5.2 Chemotherapy -- 3.5.2.1 Increasing the Concentration of Chemotherapeutic Agents in Tumor Tissue -- 3.5.3 Drug/Gene Delivery -- 3.5.3.1 Nanoparticles Used in Drug Delivery System -- 3.5.3.2 Cellulose -- 3.6 Nanotechnology in Neurodegenerative Disorders Treatment -- 3.7 Future Perspective -- 3.8 Issues with Current Nanopharmaceutical Concepts -- 3.8.1 Large-Scale Manufacturing -- 3.8.2 Biological Challenges -- 3.8.3 Intellectual Property (IP) -- 3.8.4 Biocompatibility and Safety -- 3.8.5 Government Regulations -- 3.9 Conclusion -- References -- Chapter 4 Nanomedicine Regulation and Future Prospects -- 4.1 Introduction -- 4.2 Importance of Regulation of Nanomedicine. 4.3 Regulatory Challenges Faced by Nanomaterial in Medicine -- 4.3.1 Performing Various Functions -- 4.3.2 Nanomedicine Classification Issues -- 4.3.3 Variation in Size of the Particle -- 4.3.4 Manufacturing Process -- 4.3.5 Difficulties to Create CQA -- 4.3.6 Nanotoxicology and Cellular Response -- 4.3.7 Administering Right Doses -- 4.3.8 Pharmacokinetics -- 4.3.9 Developing Guidelines -- 4.4 Nanomedicine Future Aspects -- 4.5 Challenges that Threaten the Future of Nanomedicine -- 4.5.1 Financial Crisis -- 4.5.2 Lack of Confidence -- 4.5.3 Potential Dangers -- 4.5.4 Unsuccessful Patenting -- 4.5.5 Breakdowns in the Pharmaceuticals and Financial Markets -- 4.5.6 Limited Regulation -- 4.6 Future Prospects for Nanomedicine -- 4.6.1 Emerging Nanomaterials -- 4.6.2 Personalized Nanomedicine -- 4.6.3 Nanorobots and Nanodevices -- 4.6.4 Orthopedic Augmentations and Cytocompatibility -- 4.6.5 Cardiology and Nanotechnology -- 4.6.6 Cancer and Nanotechnology -- 4.6.7 NAPT -- 4.6.8 Gene, Protein, Lab-on-a-Chip Devices -- 4.6.9 Polymeric Nanoparticles in Medicine -- References -- Chapter 5 Nanotechnology Application in Drug Delivery for Medicinal Plants -- 5.1 Introduction -- 5.1.1 Nanodrug Delivery Systems (NDDS) -- 5.2 Nanoherbals -- 5.2.1 Cucuma longa (Cucurmin) -- 5.2.2 Gingko biloba -- 5.2.3 Artemisia -- 5.2.4 Silybum marianum-Silymarin -- 5.2.5 Salvia miltiorrhiza (Danshen) -- 5.2.6 Glycyrrhiza glabra (L.) -- 5.2.7 Camellia sinensis (Green tea) -- 5.2.8 Camptotheca acuminata -- 5.2.9 Leea indica -- 5.2.10 Ziziphus mauritiana (Malay apple) -- 5.2.11 Cuscuta chinensis -- 5.3 Conclusion -- References -- Chapter 6 Nanosystems Trends in Nutraceutical Delivery -- 6.1 Introduction -- 6.2 Classification of Nutraceuticals -- 6.3 Biopharmaceutical Issues Associated with Nutraceuticals -- 6.4 Nanosystems for Delivery of Nutraceuticals -- 6.4.1 Nanoemulsions. 6.4.2 Self-Emulsifying Systems -- 6.4.3 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 6.4.4 Liposomes -- 6.4.5 Polymeric Nanoparticles -- 6.4.6 Inorganic Nanoparticles -- 6.5 Challenges -- 6.6 Market Potential -- 6.7 Conclusion and Perspective -- References -- Chapter 7 Nanoencapsulated Systems for Delivery of Phytopharmaceuticals -- 7.1 Introduction -- 7.1.1 Nanoencapsulation Techniques in Phytopharmaceuticals -- 7.1.1.1 Physical-Chemical Techniques -- 7.1.1.2 Chemicals Techniques -- 7.1.1.3 Mechanical Techniques -- 7.1.2 Characterization of Nanoencapsulates -- 7.1.2.1 Morphological Characterization -- 7.1.2.2 Physicochemical Characterization -- 7.1.3 Nanoencapsulated Systems for Free Delivery of Phytopharmaceuticals -- 7.1.4 Studies to Evaluate Phytopharmaceuticals Nanoencapsulates -- 7.2 Conclusions -- References -- Chapter 8 Topical Drug Delivery Using Liposomes and Liquid Crystalline Phases for Skin Cancer Therapy -- 8.1 Introduction -- 8.2 Liposomes for Topical Application -- 8.2.1 Development of Liposomal Nanoparticles -- 8.3 Liquid Crystals and Liquid Crystalline Nanodispersions for Topical Application -- 8.3.1 Characterization Techniques -- 8.4 Physical Methods Applied to Nanoparticles Delivery -- 8.4.1 Sonophoresis -- 8.4.2 Microneedles -- 8.5 Conclusions and Perspectives -- Acknowledgements -- References -- Chapter 9 Vesicular Drug Delivery in Arthritis Treatment -- 9.1 Introduction -- 9.2 Skin Penetration Pathways -- 9.2.1 Intercellular Pathway -- 9.2.2 Transcellular Pathway -- 9.2.3 Appendgeal Pathway -- 9.3 Principles of Drug Permeation Through Skin -- 9.4 Problems Associated with Conventional Dosage Forms -- 9.5 Novel Treatment Strategies for Arthritis -- 9.5.1 Traditional Liposomes as Skin Drug Delivery Systems -- 9.5.2 Transferosomes (Ultradeformable Liposomes) as Skin Drug Delivery Systems. 9.5.3 Ethosomes as Skin Drug Delivery Systems -- 9.5.4 Niosomes as Skin Drug Delivery Systems -- 9.6 Conclusion and Future Perspectives -- References -- Chapter 10 Perspectives of Novel Drug Delivery in Mycoses -- 10.1 Introduction -- 10.2 Role of Conventional Drugs in Antifungal Therapy -- 10.3 Mechanism of Action of Conventional Antifungals -- 10.4 Summary of Nanoparticles and Their Role in Antifungal Therapy -- 10.4.1 Lipid Nanoparticles -- 10.4.2 Liposome -- 10.4.3 Transfersomes -- 10.4.4 Transethosomes -- 10.4.5 Solid Lipid Nanoparticles (SLN) -- 10.4.6 Nanostructured Lipid Carriers (NLC) -- 10.4.7 Polymer Lipid Hybrid Nanoparticles (PLN) -- 10.4.8 Polymeric Nanoparticles -- 10.4.9 Microsponge and Nanosponge Systems -- 10.4.10 Polymeric Micelles -- 10.4.11 Polymersomes -- 10.4.12 Dendrimers -- 10.4.13 Metallic Nanoparticles -- 10.5 Other Drug Delivery Systems -- 10.5.1 Niosomes -- 10.5.2 Spanlastics -- 10.5.3 Microemulsions and Nanoemulsions -- 10.5.4 Silicon Dioxide Nanoparticles -- 10.6 Conclusion -- References -- Chapter 11 Nano-Based Drug Delivery in Eliminating Tuberculosis -- 11.1 Introduction -- 11.1.1 Latent and Active Tuberculosis -- 11.1.2 Multidrug-Resistant Tuberculosis (MDR-TB) -- 11.1.3 Extensively Drug-Resistant TB -- 11.2 Antitubercular Therapy -- 11.3 Therapies Based on Nanotechnology -- 11.3.1 Nanoparticles for Anti-TB Therapy -- 11.3.2 Advantages and Disadvantages of Nanoparticles -- 11.3.3 Types of Nanoparticles and Their Characteristics -- 11.3.3.1 TB Dendrimers -- 11.3.3.2 Cyclodextrins -- 11.3.3.3 Polymeric Micelles -- 11.3.3.4 Liposomes -- 11.3.3.5 Nanoemulsions -- 11.3.3.6 Solid Lipid Nanoparticles -- 11.3.3.7 Niosomes -- 11.3.3.8 Polymeric Nanoparticles -- 11.4 Routes of Administration of Nanoparticles -- 11.4.1 Oral Administration of Nanoparticles -- 11.4.2 Inhalational Administration of Nanoparticles. 11.4.3 Intravenous Administration of Nanoparticles. |
| Record Nr. | UNINA-9910677499803321 |
| Hoboken, NJ ; ; Beverly, MA : , : John Wiley & Sons, Inc. : , : Scrivener Publishing LLC, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
American journal of drug delivery
| American journal of drug delivery |
| Pubbl/distr/stampa | Mairangi Bay, Auckland, N.Z., : Adis International Ltd |
| Disciplina | 615.6 |
| Soggetto topico |
Drug delivery systems
Drug delivery devices Drug Therapy Pharmacology Drug Delivery Systems |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 2230-6072 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Drug delivery
Am. j. drug deliv |
| Record Nr. | UNISA-996206250503316 |
| Mairangi Bay, Auckland, N.Z., : Adis International Ltd | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Application of Nanotechnology in Drug Delivery / / Ali Demir Sezer, editor
| Application of Nanotechnology in Drug Delivery / / Ali Demir Sezer, editor |
| Autore | Ali Demir Sezer |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | IntechOpen, 2014 |
| Descrizione fisica | 1 online resource (554 pages) : illustrations |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| Soggetto non controllato |
Condensed Matter Physics
Physical Sciences Engineering and Technology Engineering Physics Nanotechnology and Nanomaterials |
| ISBN |
953-51-5756-6
953-51-1628-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910136330503321 |
|
Ali Demir Sezer
|
||
| IntechOpen, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applications of Crystal Engineering in Drug Delivery / / edited by Hisham Al-Obaidi
| Applications of Crystal Engineering in Drug Delivery / / edited by Hisham Al-Obaidi |
| Pubbl/distr/stampa | [Place of publication not identified] : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2023 |
| Descrizione fisica | 1 online resource (310 pages) |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910734349103321 |
| [Place of publication not identified] : , : MDPI - Multidisciplinary Digital Publishing Institute, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bio-targets and drug delivery approaches / / edited by Sabyasachi Maiti and Kalyan Kumar Sen
| Bio-targets and drug delivery approaches / / edited by Sabyasachi Maiti and Kalyan Kumar Sen |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, Taylor & Francis, , [2017] |
| Descrizione fisica | 1 online resource (611 pages) : illustrations |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| ISBN |
1-315-35307-5
1-315-37011-5 1-4987-3000-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Basic concepts in drug targeting / Kalyan Kumar Sen, Sabyasachi Maiti -- Chapter 2. Biological targets : identification, selection and validation / Rana Datta, Sugata Banerjee -- Chapter 3. Emerging therapeutic targets for diabetes / Sudipta Saha, Amit K. Keshari, Ashok K. Singh, Priya Singh Kushwaha, Siddhartha Maity -- Chapter 4. Prodrug strategy : an effective tool in drug delivery and targeting / Buddhadev Layek, Shubhajit Paul, Jagdish Singh -- Chapter 5. Drug-targeting strategies to CNS disorders / Somasree Ray -- Chapter 6. Natural polymers in colon targeting : approaches and future perspectives / Sougata Jana, Arijit Gandhi, Subrata Jana -- Chapter 7. Lymphatic drug targeting / Raghavendra V. Kulkarni, Biswanath Sa -- Chapter 8. New drug targets and drug delivery strategies for various ocular disorders / Subramanian Natesan, Venkateshwaran Krishnaswami, Saranya Radhakrishnan, Vaishnavi Suresh Kumar, Nirmal Sonali, Jayabalan Nirmal, Shovanlal Gayen -- Chapter 9. Bone-target drug delivery systems / Amit Kumar Nayak, Kalyan Kumar Sen -- Chapter 10. Targeted drug delivery in solid tumours : an overview and novel approaches for therapy / Mintu Pal, Lay Poh Tan -- Chapter 11. Mitochondria as an emerging target for the delivery of small therapeutic molecules / Avik Das, Sabyasachi Maiti, Kalyan Kumar Sen -- Chapter 12. Antisense oligonucleotide-mediated target specific gene silencing : design, delivery strategies and therapeutic applications / Biswajit Mukherjee, Samrat Chakraborty, Laboni Mondal, Ankan Choudhury, Bhabani Sankar Satapathy, Sanchari Bhattacharya -- Chapter 13. Biodegradable polymeric carriers for delivery of SIMA / Sanika A. Rege, Sudip K. Das, Nandita G. Das -- Chapter 14. Organic-inorganic nanocomposites for biomedical applications / Subham Banerjee, Animesh Ghosh -- Chapter 15. Carbon nanotube induced targeted drug delivery / Anish Bhattacharya and Amit K. Chakraborty -- Chapter 16. Functionalized cyclodextrin : a versatile supramolecular systems for drug delivery / Subrata Jana, Sougata Jana -- Chapter 17. Nanopolymer scaffolds as novel carriers for cells and drugs / Aum Solanki, Bhargav Hirapara, Emily Johnson, Yashwant Pathak -- Chapter 18. Bio-targets for polyionic glucan derivatives and their nano-therapeutic systems / Manabendra Dhua, Kalyan Kumar Sen, Sabyasachi Maiti -- Chapter 19. Novel carriers for targeted delivery of herbal medicines / Sankhadip Bose -- Chapter 20. Toxicological concerns related to nanoscale drug delivery systems / Sabyasachi Maiti, Sanmoy Karmakar, Kumar Anand. |
| Altri titoli varianti | Biotargets and drug delivery approaches |
| Record Nr. | UNINA-9910149366803321 |
| Boca Raton : , : CRC Press, Taylor & Francis, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioinspired and biomimetic polymer systems for drug, protein and gene delivery / / Zhongwei Gu
| Bioinspired and biomimetic polymer systems for drug, protein and gene delivery / / Zhongwei Gu |
| Autore | Gu Zhongwei |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH Verlag, , 2015 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina | 615.6 |
| Soggetto topico | Drug delivery systems |
| ISBN |
3-527-67272-9
3-527-67275-3 3-527-67273-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bioinspired and Biomimetic Polymer Systems for Drug and Gene Delivery; Contents; List of Contributors; Preface; Chapter 1 Backbone Degradable and Coiled-Coil Based Macromolecular Therapeutics; 1.1 Introduction; 1.2 Water-Soluble Polymers as Carriers of Anticancer Drugs; 1.2.1 First Generation Conjugates - Design, Synthesis, and Activity; 1.2.2 Analysis of Design Factors That Need Attention; 1.2.2.1 Design of Conjugates for the Treatment of Noncancerous Diseases; 1.2.2.2 Combination Therapy Using Polymer-Bound Therapeutics; 1.2.2.3 New Targeting Strategies
1.2.2.4 Relationship Between Detailed Structure of the Conjugates and Their Properties1.2.2.5 Impact of Binding a Drug to a Polymer on the Mechanism of Action; 1.2.2.6 Mechanism of Internalization and Subcellular Trafficking; 1.2.2.7 Relationship Between the Molecular Weight of the Carrier and the Efficacy of the Conjugate; 1.2.3 Design of Second Generation Conjugates - Long-Circulating and Backbone Degradable; 1.2.3.1 RAFT Copolymerization for the Synthesis of Conjugates; 1.2.3.2 Click Reactions for Chain Extension into Multiblock Copolymers 1.2.3.3 Biological Properties of Long-Circulating Macromolecular Therapeutics1.2.4 Summary of Part 2 and Future Prospects; 1.3 Drug-Free Macromolecular Therapeutics - A New Paradigm in Drug Delivery; 1.3.1 Biorecognition in Hybrid Polymer Systems; 1.3.2 Coiled-Coils in Biomedical Systems; 1.3.3 Coiled-Coil Based Drug-Free Macromolecular Therapeutics: Design, In Vitro, and In Vivo Activity; 1.3.4 Potential, Limitations, and Future Prospect of Drug-Free Macromolecular Therapeutics; 1.4 General Summary and Outlook; Acknowledgments; References Chapter 2 Dendritic Polymers as Targeting Nanoscale Drug Delivery Systems for Cancer Therapy2.1 Introduction; 2.2 Functional Dendritic Polymers Based Drug Delivery Vehicles for Targeting Tumor Therapy via EPR Effect; 2.2.1 Functional Dendritic Polymers for Encapsulation of Anticancer Drugs; 2.2.2 Chemical Conjugation Functional Dendritic Polymers as Drug Delivery Systems; 2.3 Tumor Targeting Moieties Functionalized Dendritic Drug Delivery Vehicles for Cancer Therapy; 2.4 Conclusion; References; Chapter 3 Composite Colloidal Nanosystems for Targeted Delivery and Sensing; 3.1 Introduction 3.1.1 Working Toolkit3.1.2 Engineering a Multifunctional Carrier; 3.2 Objective; 3.3 Cellular Behavior of the Carrier; 3.3.1 Intracellular Fate; 3.3.2 Biocompatibility; 3.4 Applications; 3.4.1 Delivery with Multifunctional PEM Capsules; 3.4.1.1 Magnetic Targeting and Magnetofection; 3.4.1.2 Strategies for Controlled Opening; 3.4.2 Intracellular Ion Sensing; 3.5 Conclusions; Abbreviations; References; Chapter 4 Polymeric Micelles for Cancer-Targeted Drug Delivery; 4.1 Introduction; 4.2 Micelle Formulations in Clinical Development; 4.3 Particle Size of Micelles; 4.4 Morphology of Micelles 4.5 Targeting Design of Micelles for Enhanced Accumulation and Cell Internalization |
| Record Nr. | UNINA-9910140484403321 |
|
Gu Zhongwei
|
||
| Weinheim, Germany : , : Wiley-VCH Verlag, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
